Internal Medicine, Infectious Disease · Chicago, IL
NPI
1356370233
Since 2006
Specialty
Internal Medicine, Infectious Disease
Code 207RI0200X
Group practices
2
Medicare group memberships
Hospitals
0
Hospital affiliations
836 W Wellington Ave
Chicago, IL, 60657
Phone (773) 296-7039
Groups this clinician bills Medicare through
Medicare paid, 2022
$2,645
32 services
Medicare patients, 2022
26
Average age 74
Drug cost, 2024
$2.3M
1,240 prescriptions
Company payments, 2025
$45K
From 14 companies
Procedures and visits billed to Original Medicare, 2022
In 2022, the most common Medicare service billed by Catherine M Creticos was code 99232 (hospital e&m - subsequent), 17 times for 15 patients. In total Catherine M Creticos billed 32 services in 4 codes, and Medicare paid $2,645.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 17 | 15 | $59.85 | $1,017 |
Medicare prescription drug claims, 2024
In 2024, the drug Catherine M Creticos prescribed most often to Medicare patients was Genvoya (Elviteg/Cob/Emtri/Tenof Alafen), with 71 prescriptions and refills. In total Catherine M Creticos wrote 1,240 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Genvoya Elviteg/Cob/Emtri/Tenof Alafen | 71 | 71 | Under 11 | $306K |
| Prezcobix Darunavir/Cobicistat | 63 | 63 | Under 11 | $160K |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | 62 | 62 | Under 11 | $263K |
| Gabapentin Generic | 46 | 77 | Under 11 | $575 |
| Atorvastatin Calcium Generic | 41 | 95 | 11 | $313 |
| Dovato Dolutegravir Sodium/Lamivudine | 35 | 35 | Under 11 | $109K |
| Tivicay Dolutegravir Sodium | 32 | 32 | Under 11 | $102K |
| Trazodone Hcl Generic | 32 | 48 | Under 11 | $437 |
| Symtuza Darunavir/Cob/Emtri/Tenof Alaf | 30 | 32 | Under 11 | $166K |
| Trogarzo Ibalizumab-Uiyk | 27 | 27 | Under 11 | $293K |
| Isentress Raltegravir Potassium | 27 | 27 | Under 11 | $57K |
| Descovy Emtricitabine/Tenofov Alafenam | 25 | 35 | Under 11 | $79K |
| Omeprazole Generic | 21 | 45 | Under 11 | $325 |
| Emtricitabine-Tenofovir Disop Emtricitabine/Tenofovir (Tdf) | 20 | 20 | Under 11 | $969 |
| Darunavir Generic | 19 | 19 | Under 11 | $26K |
Brand drugs: 532 claims; generic drugs: 708 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Catherine M Creticos $45K ($45K in general payments such as food, travel and fees) from 14 companies. The largest payer was Gilead Sciences, Inc. with $38K.
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. GILD | 61 | $38K |
| ViiV Healthcare Company GSK | 58 | $5,757 |
| Theratechnologies Inc. THTX | 11 | $183 |
| Merck Sharp & Dohme LLC MRK | 7 | $158 |
| Napo Pharmaceuticals Inc | 6 | $119 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 4 | $83.67 |
| EMD Serono, Inc. MRK.DE | 4 | $63.8 |
| Amgen Inc. AMGN | 2 | $39.15 |
| Exact Sciences Corporation EXAS | 1 | $24.4 |
| Lundbeck LLC | 1 | $20.9 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.